IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma
Oct 19, 2026, 06:00 ET Prior tebentafusp (2L) (N=15) All presentations will take place on Saturday, October 24th, 2026, 12:00-12:45pm (CEST): 2092P (Poster Presentation)Title: Neoadjuvant Darovasertib in Primary Uveal Melanoma: Follow-Up Data from the Phase 2 OptimUM-09 Study Presenting Author - Mark Shackleton, MBBS, PhD, FRACP, Department of Oncology,…